Sign in
CompletedPhase 2

A 12-Week Open-Label Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Skin-Predominant Dermatomyositis

Key facts

Who runs it
Priovant Therapeutics, Inc.
Where
Scottsdale, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 2
People taking part
5 people enrolled
Started
28 Aug 2024
Ended
28 Feb 2025
Type of study
Interventional
Treatments tested
  • Brepocitinib
Record updated
20 May 2025

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • A diagnosis of dermatomyositis according to 2017 EULAR/ACR Classification Criteria for Idiopathic Inflammatory Myopathies
  • Active cutaneous manifestations of dermatomyositis
  • Adult subjects (18-75 years old)
  • Weight > 40 kg to < 130 kg, and with a body mass index (BMI) < 40 kg/m2

Who cannot take part

  • Dermatomyositis with irreversible muscle involvement; History of:
  • Any lymphoproliferative disorder
  • Active malignancy
  • History of cancer within 5 years prior to randomization (exceptions for basal cell carcinoma, squamous cell carcinoma, ductal carcinoma in situ of the breast, carcinoma in situ of the uterine cervix, or thyroid carcinoma.) Cancer-associated dermatomyositis
  • Overlap myositis/connective tissue disease (except for overlap with Sjögren's syndrome)
  • Participants at a risk of thrombosis or cardiovascular disease
  • Participants with active or recent infections
  • Dermatomyositis with end-stage organ involvement
  • Participants with a high risk for herpes zoster reactivation

Where in United States

  • Scottsdale, ArizonaHospital not named in the registry

About the trial

What the trial wants to find out

This is a prospective, 12-week, open-label, single-arm study. The study population comprises individuals with refractory skin disease characteristic of dermatomyositis with no to minimal muscle involvement. After an up to 8-week Screening Period, eligible participants will receive brepocitinib 30 mg orally (PO) QD for 12 weeks.

The group in the trial

  • BrepocitinibTreatment being tested

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A 12-Week Open-Label Pilot Study to Investigate the Efficacy and Safety of Oral Brepocitinib in Adults With Skin-Predominant Dermatomyositis
Record updated
20 May 2025